



OPEH&W HealthPlan

Rx Review

10/15/2020

Results: TEAM's Exclusion Drug List

Drug Name	Common Uses	#Rxs	Submitted Cost for all unique claims	Cost of Medication if filled for one year	Cost of Alternative if filled for one year
Auvi-Q	Allergic Reactions	19	\$129,470	\$223,630	\$11,400
Fluocinonide 0.1% cream	Skin Conditions	9	\$26,478	\$79,434	\$810
Chlorzoxazone 250/375mg	Muscle Spasms	10	\$25,844	\$77,532	\$1,500
Rayos	Arthritis	1	\$6,298	\$75,571	\$120
Pennsaid	Knee Pain	4	\$12,269	\$73,614	\$2,040
Duexis	Arthritis	2	\$6,012	\$72,143	\$480
Belsomra	Insomnia	13	\$6,065	\$66,762	\$1,560
Bensal 3% Ointment	Skin Irritation	1	\$5,000	\$60,000	\$240
Concerta (methylphenidate)	ADHD	8	\$3,311	\$39,726	\$7,910
Focalin XR (dexamethylphenidate)	ADHD	6	\$3,022	\$36,267	\$7,704
Naproxen Sodium CR 500mg	Moderate Pain	4	\$2,830	\$33,961	\$2,400
Welchol	High Cholesterol	4	\$2,294	\$27,533	\$1,253
Androgel	Low Testosterone	3	\$2,027	\$24,328	\$2,160
Dexilant	Acid Reflux / GERD	5	\$1,730	\$21,247	\$1,200
Celebrex (celecoxib)	Arthritis	2	\$3,303	\$19,820	\$1,248
Prilosec	Acid Reflux / GERD	3	\$2,424	\$15,613	\$720
Cyclobenzaprine ER	Muscle Spasms	1	\$1,201	\$14,415	\$1,200
Hysingla ER	Narcotic Analgesic	2	\$1,151	\$13,812	\$720
Protonix	Acid Reflux / GERD	1	\$1,144	\$13,727	\$240
Gralise	Shingles	1	\$1,071	\$12,851	\$648

-- continued on next slide --

Formulary exclusions can be overridden for medical necessity and are appealable;
Plan exclusions are not appealable and cannot be overridden for medical necessity.

Results: TEAM's Exclusion Drug List

Drug Name	Common Uses	#Rxs	Submitted Cost for all unique claims	Cost of Medication if filled for one year	Cost of Alternative if filled for one year
Tegretol XR (carbamazepine)	Seizures	2	\$875	\$10,506	\$2,280
Jublia	Nail Fungul Infection	1	\$697	\$8,369	\$720
Restasis	Dry Eye	1	\$1,907	\$7,629	\$360
Benicar (olmesartan)	High Blood Pressure	2	\$1,799	\$7,195	\$648
Norco (hydrocodone/acetamin)	Narcotic Analgesic	2	\$563	\$6,759	\$720
Abilify (aripiprazole)	Schizophrenia / Bipolar	1	\$540	\$6,482	\$396
Horizant	Restless Let Syndrome	1	\$468	\$5,619	\$216
Androderm	Low Testosterone	1	\$749	\$4,495	\$720
Dilantin (phenytoin)	Seizures	2	\$776	\$4,443	\$840
Crestor (rosuvastatin)	High Cholesterol	1	\$965	\$3,859	\$313
Nexium	Acid Reflux / GERD	1	\$939	\$3,758	\$240
Singulair (montelukast)	Asthma	1	\$825	\$3,298	\$240
Vimovo	Arthritis	1	\$146	\$1,750	\$600
Qnasl	Allergiers	2	\$589	\$1,497	\$102
Omnaris	Allergies	1	\$469	\$1,408	\$51
Zonalon 5% Cream	Skin Conditions	1	\$800	\$800	\$30
Dymista	Allergies	1	\$244	\$733	\$51
Doxepin 5%	Atopic Dermatitis	1	\$727	\$727	\$30
Doral	Insomnia	1	\$31	\$372	\$120
Tamiflu (oseltamivir)	Influenza	1	\$233	\$233	\$102
Plan Cost Avoidance Due to Ability to Exclude Drugs		124	\$257,289	\$1,081,921	\$54,333

Excluding egregiously priced drugs saved an **actual \$257,289 in cost avoidance!** “Had” the claims been filled appropriately for 12 months, the cost would have been \$1,081,921; but was avoided.

Rx Financial Highlights

Utilization	FYE June 2019	FYE June 2020	% Change	Comments
Number eligible	7,804	6,685	-14%	Decrease in member count may affect pmpm's by making them appear higher
Percent utilizing	93%	90%	-3%	
Trends				
<i>Gross PMPM</i>	\$155	\$163	5%	National trend is 11%
<i>Plan Paid PUPM</i>	\$144	\$153	6%	Taking it to a "per utilizer" smooths out the decrease in eligibles
<i>Plan Paid PMPM</i>	\$135	\$139	3%	Benchmark is 9%; for this to be 3% when lives decreased -14% is remarkable
<i>Plan Paid PMPM Net Net^</i>	\$108	\$111	-20%	Includes rebates; Difference between \$139 Plan Paid PMPM and \$111 Plan Paid PMPM Net Net^
<i>Plan Paid PMPM w/o Specialty</i>	\$83	\$87	6%	
<i>Specialty Plan Paid PMPM</i>	\$52	\$51	-1%	105 members using specialty in current period, decrease of 12 members
<i>Claims PMPY</i>	14.9	14.9	0%	
<i>Total Claims PMPY (counts 90 ds as '3')</i>	22.3	22.6	2%	
<i>Generic Dispense Rate</i>	85.9%	86.4%	0.5%	Accounts for ~\$166,722 in savings to the Plan.
Drug Spend				
Gross Costs	\$14,542,916	\$13,076,842	-10%	
<i>Specialty (included above)</i>	\$4,871,734	\$4,296,999	-12%	Specialty cost drivers: PKU +\$89k, PAH +\$81k, Blood Cell Deficiency + \$55k
Plan Paid	\$12,608,601	\$11,114,826	-12%	Conventional cost drivers include Biguanides + \$217k, GLP-1 +\$46k; Anticonvulsants down \$180k
<i>Specialty (included above)</i>	\$4,857,590	\$4,104,015	-16%	Specialty PAP manufacturer assistance provided in excess of \$623,000 gross in current year and \$48,000 in previous year
Member Paid	\$1,934,315	\$1,962,016	1%	
Rebates Paid				
<i>Rebates^</i>	\$2,517,014	\$2,244,279	-11%	Impacted by decrease in specialty brand claims
<i>Plan Paid After Rebates</i>	\$10,091,587	\$8,870,547	-12%	Includes rebates

^ "Net Net" means rebates are factored in and it reduces plan costs

Rx Financial Highlights *(continued)*


Cost Share	FYE June 2019	FYE June 2020	% Change	Comments
<i>Member</i>	13%	15%	1.7%	
<i>Member w/o Specialty</i>	20%	20%	0.3%	
Average Gross Costs				
<i>Avg Gross Cost /R30 Conv Brand</i>	\$325	\$355	9%	
<i>Avg Gross Cost /R90 Conv Brand</i>	\$699	\$796	14%	R90 brand cost drivers include Humalog +\$465/rx, Levemir +\$282/rx, Janumet +\$257/rx, Toujeo +\$210/rx, Humalog +202/rx
<i>Avg Gross Cost /Mail Conv Brand</i>	\$1,027	\$921	-10%	
<i>Avg Gross Cost /R30 Conv Generic</i>	\$27	\$26	-2%	
<i>Avg Gross Cost /R90 Conv Generic</i>	\$60	\$73	22%	R90 generic cost driver was Metformin Gastric with 74 rx, avg \$4,410/rx
<i>Avg Gross Cost /Mail Conv Generic</i>	\$68	\$68	1%	
<i>Avg Gross Cost/ Spec Brand Rx</i>	\$7,001	\$7,360	5%	
<i>Avg Gross Cost/ Spec Generic Rx</i>	\$1,992	\$4,003	101%	Specialty cost driver was Abiraterone (prostate cancer) with 9 new claims that average \$7,167/rx
Claim Counts				
<i>Claims</i>	116,418	99,573	-14%	Reflective of lower eligible members and utilization percent
<i>Adjusted Claims (counts 90 ds as '3')</i>	173,770	151,343	-13%	
<i>R30 Brand</i>	12,780	10,549	-17%	
<i>R30 Generic</i>	72,769	61,278	-16%	
<i>R30 OTC</i>	1,438	1,155	-20%	
<i>R90 Brand</i>	2,265	1,782	-21%	
<i>R90 Generic</i>	23,060	21,156	-8%	
<i>R90 OTC</i>	260	278	7%	
<i>Mail Brand</i>	387	312	-19%	
<i>Mail Generic</i>	2,645	2,298	-13%	
<i>Mail OTC</i>	59	59	0%	
<i>Specialty Brand</i>	682	624	-9%	Autoimmune down 54 Rx
<i>Specialty Generic</i>	73	82	12%	

Benchmarks

Rx SPEND	FYE June 2019	FYE June 2020	BENCHMARK
Gross Cost PMPM (Trend)	4.6%	5.0%	11%*
Plan Paid PMPM (% Change)	3.3%	2.9%	9%*
Plan Paid PMPM	\$135	\$139	\$118 - \$188
Claims PMPY	14.9	14.9	10 - 14
Average Plan Paid Per Rx	\$108	\$112	\$131 - \$189
Average Member Paid Per Rx	\$17	\$20	\$8 - \$15
SPECIALTY PHARMACY			
Average Plan Paid Per Specialty Rx	\$6,434	\$5,813	\$6,339 - \$9,525
Average Member Paid Per Specialty Rx	\$19	\$273	\$21 - \$167
Specialty Plan Paid PMPM	\$51.87	\$51.16	\$41 - \$76
CLAIMS			
90-Day Supply Claims	25%	26%	7% - 20% <i>ESI Benchmark is only Mail Order</i>
Generic Dispensing Rate	85.9%	86.4%	83.5% - 86.6%


** Specialty costs affecting trend; trend number derived by TEAM Pharmacy Consulting, Inc. polling underwriters at Carriers and PBMs
Express Scripts Benchmark Data for Local Government, July 2019 – June 2020*

Generic Dispense Rate



Accounts for \$133,378 in savings to OPEH&W over 5 Years


Specialty Pharmacy: Common Uses



Autoimmune includes Rheumatoid Arthritis, Plaque Psoriasis, Crohn's Disease, Ulcerative Colitis, Psoriatic Arthritis, and Ankylosing Spondylitis.

Top Diabetic Therapy Classes by Plan Paid

■ FYE June 2020
■ FYE June 2019




Diabetic Cost Drivers include Biguanides (Metformin ER Gastric) which averaged \$15/unit with 27 utilizers

Top Conventional Classes by Plan Paid

(Diabetic Drugs Excluded)

■ FYE June 2020

■ FYE June 2019



Significant decrease in Anticonvulsants due to release of generic Lyrica. Avg Plan Cost per Lyrica claim in prior period was \$530; avg Plan Cost of its generic in current period is \$150 per claim.

There was only a decrease of 61 net claims for Lyrica/generic Lyrica; or Pregabalin.



Key achievements – OPEH&W FY20 Savings

SUCCESS	PROGRAM	VALUE DELIVERED
1 Action #1	• Utilization Management	• \$998K
2 Action #2	• SaveonSP	• \$554K
3 Action #3	• Brand-to-Generic Program	• \$195K
4 Action #4	• SafeGuardRx Programs	• \$357K

FY20 HealthCare Savings = \$2.1M



FY2020 Clinical Savings

Program	Metric	2019-07-01 - 2020-06-30
Advanced Utilization Management Total		
	Rx Requiring Action	1,898
	Ingredient Cost Savir	\$1,078,494
	Plan Savings	\$998,146
Prior Authorization		
	Rx Requiring Action	268
	Ingredient Cost Savings	\$315,657
	Plan Savings	\$321,697
Step Therapy		
	Rx Requiring Action	333
	Ingredient Cost Savings	\$96,372
	Plan Savings	\$80,371
Drug Quantity Management		
	Rx Requiring Action	1,026
	Ingredient Cost Savings	\$212,367
	Plan Savings	\$188,933
Misc		
	Rx Requiring Action	271
	Ingredient Cost Savings	\$454,098
	Plan Savings	\$407,145



Express Insights: Deeper Insights based on Integrated (medical+pharmacy) data.

TYPE IN ORG ID All
 TYPE IN CARRIER ID 7303
 CLIENT NAME OKLAHOMA PUBLIC EMP H&W
 CUSTOMER GROUP CD-LA
AGE GROUP OVERALL

CLIENT INFORMATION

Mean Age: 39
 Avg. Membership: 7,100

OPERATIONAL STATISTICS

Reporting Period (Current): January 1, 2019– December 31, 2019



Conditions	Pipeline Drug	Manufacturer	Formulation	Est Cost	Anticipated Approval	Unique Patients	% Client Lives*
B cell non-Hodgkin lymphoma	lisocabtagene maraleucel (Breyanzi)*	Bristol-Myers Squibb	injectable (IV)	\$373K - one time infusion	11/16/2020	4	0.06%
Bladder cancer	nadofaragene firadenovec (Adstiladrin)*	Ferring	intravesical	\$300K per year	5/25/2020	9	0.13%
Childhood X-linked adrenoleukodystrophy	elivaldogene tavalentivec (LentiD)	Bluebird Bio	injectable (IV)	\$2M - one time infusion	2021	0	0.00%
Chronic lymphocytic leukemia in relapse	lisocabtagene maraleucel (Breyanzi)*	Bristol-Myers Squibb	injectable (IV)	\$373K - one time infusion	2021	2	0.03%
Duchenne muscular dystrophy	SRP-9001	Sarepta	injectable (IV)	\$2M - one time infusion	2021	0	0.00%
Hemophilia B	etranacogene dezaparvovec (EtranaDez)	uniQure	injectable (IV)	\$2M - one time infusion	2021	0	0.00%
	fidanacogene elaparvovec (SPK-9001)*	Spark Therapeutics / Pfizer	injectable (IV)	\$2M - one time infusion	2021	0	0.00%
Hemophilia A	valoctocogene roxaparvovec (Roctavian)*	BioMarin Pharmaceuticals	injectable (IV)	\$2.5M - one time infusion	8/21/2020	1	0.01%
Mantle cell lymphoma	KTE-X19	Kite	injectable (IV)	\$400K - one time infusion	8/10/2020	0	0.00%
Multiple myeloma in relapse	idecabtagene vicleucel (Ide-cel)*	Bluebird Bio	injectable (IV)	\$475K - one time infusion	2021	0	0.00%
	JNJ-4528 (LCAR-838M)	Janssen	injectable (IV)	\$475K - one time infusion	2021	0	0.00%
Prostate cancer	aglatimagene besadenovec (ProstAtak)	Advantagene	intra-tumoral	\$300K per year	2021	48	0.68%
Unspecified peripheral vascular disease or..	beperminogene perplasmid (AMG0001)	Mitsubishi Tanabe Pharma	injectable (IM)	\$300K per year	2021	53	0.75%

Legend:

If % is less than 0.01%, the number is represented in **ORANGE**.

*Drugs with breakthrough therapy designation (alone or in combination can treat serious conditions that have preliminary clinical evidence that demonstrates substantial improvement over existing therapies) Gene therapy pipeline drugs not included in report due ultra low patient volume - eladocogene exuparvovec (AGIL-AADC) , OTL-101

GENE THERAPY PIPELINE



OPEH&W

In **2021**, estimated **0.24%** of members have one or more of the **10** conditions related to **12** gene therapy pipeline drugs.

Less than **25.00%** of patients with related conditions may utilize pipeline drugs resulting in estimated spend of up to **\$456 PMPY**

Cost Estimates by Category & Condition

Drug Name	Condition	Estimated Spend
Roctavian (valoctocogene roxaparvec)	Hemophilia A	\$2.0M
Breyanzi (lisocabtagene maraleucel)	Chronic lymphocytic leukemia	\$0.4M
	Large B-cell NHL	\$0.4M
Instiladrin/Adstiladrin (nadofaragene firadenov..)	Bladder cancer	\$0.3M
Ide-cel (idecabtagene vicleucel)	Multiple myeloma	\$0.0M
LCAR-838M (JNJ-4528)	Multiple myeloma	\$0.0M
Tecartus (brexucabtagene autoleucel)	Mantle cell lymphoma	\$0.0M
AGIL-AADC (eladocogene euparvec)	AADC deficiency	\$0.0M
Lenti-D (elivaldogene tavalentec)	Cerebral ALD	\$0.0M
SRP-9001	Duchenne muscular dystrophy	\$0.0M
EtranaDez AMT-061 (etranacogene dezaparvo..)	Hemophilia B	\$0.0M
SPK-9001 (fidanacogene elaparvec)	Hemophilia B	\$0.0M



Gene Therapy Pipeline Forecast

OPEH&W			Spend Year 2021	Input Client Size 6,685	Custom Condition Patient Count Yes				
# of Drugs	# of Patients with Conditions	# of Min Patients Utilizing Drugs	# of Max Patients Utilizing Drugs	Min Total Cost for Drugs	Max Total Cost for Drugs	Min Additional PMPY Cost	Max Additional PMPY Cost		
12	16	0	4	\$0.0M	\$3.0M	\$0.00	\$455.65		
Condition	Drug Name	Approval Year	Condition Patient Count	Drug Patient Count Min	Drug Patient Count Max	Total Cost for Drugs Min	Total Cost for Drugs Max	Additional PMPY Cost Min	Additional PMPY Cost Max
Hemophilia A	Roctavian (valoctocogene roxaparvovec)	2020	1	0	1	\$0	\$2,000,000	\$0.00	\$299.18
Bladder cancer	Instiladrin/Adstiladrin (nadofaragene firadenovec)	2021	9	0	1	\$0	\$300,000	\$0.00	\$44.88
Mantle cell lymphoma	Tecartus (brexucabtagene autoleucel)	2020	0	0	0	\$0	\$0	\$0.00	\$0.00
Large B-cell NHL	Breyanzi (lisocabtagene maraleucel)	2020	4	0	1	\$0	\$373,000	\$0.00	\$55.80
Multiple myeloma	Ide-cel (idecabtagene vicleucel)	2021	0	0	0	\$0	\$0	\$0.00	\$0.00
Multiple myeloma	LCAR-838M (JNJ-4528)	2021	0	0	0	\$0	\$0	\$0.00	\$0.00
Chronic lymphocytic leukemia	Breyanzi (lisocabtagene maraleucel)	2021	2	0	1	\$0	\$373,000	\$0.00	\$55.80
Cerebral ALD	Lenti-D (elivaldogene tavalentivec)	2021	0	0	0	\$0	\$0	\$0.00	\$0.00
Duchenne muscular dystrophy	SRP-9001	2021	0	0	0	\$0	\$0	\$0.00	\$0.00
Hemophilia B	EtranaDez AMT-061 (etranacogene dezaparvov...)	2021	0	0	0	\$0	\$0	\$0.00	\$0.00
Hemophilia B	SPK-9001 (fidanacogene elaparvovec)	2021	0	0	0	\$0	\$0	\$0.00	\$0.00
AADC deficiency	AGIL-AADC (eladocogene exuparvovec)	2021	0	0	0	\$0	\$0	\$0.00	\$0.00



Decreasing the amount of opioids dispensed – AOM Successes


56% reduction in the average day supply per claim for first time short acting opioids

91% of short acting opioid patients prescribed an opioid for the first time exceeding a 7-day supply and were successfully reduced to a 7-day supply or less

46% of patients prescribed a long-acting opioid as initial therapy were redirected to safer, short-acting

9% claims paid for >7 day supply with PA override short acting opioids

Avg Days Supply per Claim



886
member
education
letters mailed



279
drug disposal
bags mailed



138
Opioid Alerts Sent to
Physicians*

*May represent alerts generated from Advanced Opioid Management and RationalMed



Confidential Information

© 2020 Express Scripts Holding Company. All Rights Reserved.



EXPRESS SCRIPTS®

CHAMPIONS
FOR
BETTER®


Advanced Opioid Management Savings Analysis

Program Savings	
Drug Cost Savings	\$5,516
Medical Cost Avoidance*	\$50,156
Total Estimated Savings	\$55,672

*Medical Cost Savings does not include Opioid 2.0 Rules at this time

PMPM Savings	
Estimated Pharmacy PMPM Savings	\$0.07
Estimated Medical PMPM Savings	\$0.63
Total Estimated PMPM Savings	\$0.69

Total Program Savings




Total Estimated Savings \$55.7K

Estimated \$0.69 PMPM Savings




Therapeutic Resource Center Statistics

Contact Rates



Counseling Acceptance Rates



Clinical Strategy	Opportunities	Activities	Successful Contact	Unsuccessful Contact	Accepted Counseling	Declined Counseling	Other
MEDICATION-ASSISTED TREATMENT	3	3	0	3	0	0	0
LONG ACTING OPIOIDS, DUPLICATE CARE	1	1	1	0	1	0	0
SHORT ACTING OPIOIDS, TOLERANCE RISK	8	8	0	8	0	0	0
EARLY THERAPY ESCALATION	1	1	0	1	0	0	0
ACCUMULATION RISK	22	24	2	22	1	0	1
TOTAL	35	37	3	34	2	0	1